Multiple sclerosis research.
Cortexin observations, Bemitil patent cases and the historical metabolic-treatment literature, with their evidence boundaries intact.
What the direct MS sources show
The earlier Cortexin study reported no significant EDSS change. Later functional observations and a Bemitil patent remain limited by study design, incomplete reporting and concurrent treatments. None of these records establishes remyelination or prevention of disability progression.
Effect of Cortexin on neuroplasticity in multiple sclerosis
Format: Publisher article and Russian PDF · Reviewed: Full article reviewed
S. V. Kotov, T. I. Yakushina, V. Yu. Lizhdvoy · Effective Pharmacotherapy. Neurology and Psychiatry. 2009;(3):14–16
EDSS did not change significantly. Beck depression scores fell from 17.6±1.3 to 12.9±1.4 and EQ-5D rose from 0.41±0.07 to 0.73±0.03 (reported p<0.05). These are uncontrolled symptom and quality-of-life observations, not evidence of remyelination.
- Population / setting
- 20 adults with relapsing-remitting MS in stable remission; 7 men and 13 women, ages 27–43
- What was checked
- Source text reviewed at the access level stated; no independent verification of patient data.
Limitations & review scope
- Open prospective study without a control group, randomization or blinding.
- Participants were already in remission; stable EDSS does not demonstrate prevention of progression.
- No adverse events were observed in this small sample; safety and disease modification are not established.
Source checked 2026-10-03. This is a source-linked record, not a completed evidence review.
Neuropeptide immunocorrection in patients with multiple sclerosis
Cortexin tissue-derived peptide preparation
Format: Open-access journal PDF; Zenodo repository · Reviewed: Full article read; motor table visually checked
M. A. Artykova, S. A. Beknazarov · Scientific and Innovative Therapy. 2025;(2):3–9. Bukhara State Medical Institute; Zenodo deposit 5 June 2025
After three courses, the authors report upper-limb motor-score gains of 1.4 versus 0.8 points and lower-limb gains of 1.8 versus 0.9, with reported p<0.05. The proportion described as having reduced work capacity fell from 71.7% to 31.1% with adjunct Cortexin, versus 75.5% to 53.1% in controls. These are reported functional signals, not evidence of disease modification.
- Population / setting
- 63 adults with MS, ages 18–59: 33 standard therapy plus Cortexin; 30 standard therapy alone
- What was checked
- Methods, results, tables and references reviewed. Randomization, blinding and allocation procedures are not described; this is not classified as a randomized trial.
Limitations & review scope
- Small comparison with unclear allocation, baseline comparability, concomitant therapy and assessment timing; no placebo or blinding described.
- Motor scale, variance and statistical methods are insufficiently specified. Percentages lack underlying counts; immune-marker claims have no numerical table.
- No longitudinal MRI lesion, relapse-rate or EDSS progression outcomes are reported. Safety reporting is insufficient; this does not establish an MS treatment or replacement for disease-modifying therapy.
- A same-title 2021 Artykova–Rakhmatov report exists; cohort overlap remains unresolved and is not counted as independent replication.
Source checked 2026-10-03. This is a source-linked record, not a completed evidence review.
Pharmaceutical composition and method for treating chronic fatigue syndrome due to its application
Format: Patent full text · Reviewed: Clinical example and patent dates checked
O. V. Dorozhko, G. I. Kovalev, R. M. Salimov · RU2267319C2. Filed 15 July 2003; application published 10 February 2005; granted 10 January 2006
Example 5 describes a 47-year-old woman with MS receiving Bemitil alongside piracetam, pentoxifylline, B vitamins and massage. The patent reports improvements in strength, coordination, cognition, mood and sleep. It supplies neither a controlled MS trial nor complete results for all ten MS cases.
- Population / setting
- Patent reports 10 MS cases and a separate 10-person chronic-fatigue group; one MS case described
- What was checked
- Source text reviewed at the access level stated; no independent verification of patient data.
Limitations & review scope
- Patent assertions, not a peer-reviewed efficacy trial; multiple simultaneous interventions prevent attribution.
- The described baseline brain MRI had no pathological changes, making a claim of MRI remission uninterpretable.
- Animal MPTP, glutamate and haloperidol experiments are not experimental autoimmune demyelination models.
Source checked 2026-10-03. This is a source-linked record, not a completed evidence review.
Related disease research: do not pool it with MS
The SLE paper, patent and dissertation belong to a potentially overlapping program. They are not three independent confirmations. Hereditary neuromuscular disease observations and healthy-donor cell experiments answer different questions.
The effect of bemetil on production of DNA antibodies in patients with systemic lupus erythematosus
Format: Indexed English abstract · Reviewed: Abstract reviewed
T. A. Lisitsyna, A. D. Durnev, M. M. Ivanova, A. I. Speranskii, S. B. Seredenin, V. A. Nasonova · Experimental and Clinical Pharmacology. 1999;62(5):38–41. PMID 10572751
The abstract reports reduced anti-DNA antibodies and improvements in SLEDAI-1/ECLAM disease-activity measures in Bemitil-containing treatment groups. Background treatment included prednisolone, with or without cyclophosphamide. Numerical effect sizes are not available in the abstract.
- Population / setting
- 61 people with SLE; four groups of 15, 15, 15 and 16; eight-week comparison
- What was checked
- Source text reviewed at the access level stated; no independent verification of patient data.
Limitations & review scope
- SLE is a different disease; these findings do not establish efficacy in MS.
- Allocation and blinding cannot be established from the abstract; concomitant therapy complicates attribution.
- Likely related to the 1997 dissertation and 2000 patent: do not count these as independent replication.
Source checked 2026-10-03. This is a source-linked record, not a completed evidence review.
Method of treating systemic lupus erythematosus
Format: Russian patent reproduction · Reviewed: Patent text reviewed
T. A. Lisitsyna and colleagues · RU2157684C2. Filed 22 December 1997; published 20 October 2000
The patent describes four treatment groups using glucocorticoids with or without cyclophosphamide and Bemitil. It reports improvements in selected clinical and laboratory signs and anti-DNA antibodies in the Bemitil groups. This appears to describe the same research program as the 1999 paper.
- Population / setting
- 61 SLE patients treated at the Institute of Rheumatology, 1993–1997
- What was checked
- Source text reviewed at the access level stated; no independent verification of patient data.
Limitations & review scope
- Patent reproduction; allocation concealment and blinding are not established. Treatment choice also reflected disease severity.
- Numerous outcomes and unequal follow-up periods prevent a simple comparative relapse-rate interpretation.
- Not an MS study or independent confirmation of the 1999 SLE report.
Source checked 2026-10-03. This is a source-linked record, not a completed evidence review.
Bioenergetic disturbances and their correction in neuromuscular diseases
Format: Russian dissertation abstract, OCR reproduction · Reviewed: Author metadata and relevant text reviewed
L. A. Saikova · Doctoral dissertation author abstract. Saint Petersburg, 1993
The dissertation describes bioenergetic and enzyme-marker changes during treatment, including Bemitil comparisons. It extends the neuromuscular research context of the 1991 and 1992 publications; biochemical changes alone do not establish sustained functional benefit.
- Population / setting
- Neuromuscular disease research program, including hereditary muscular dystrophies
- What was checked
- Source text reviewed at the access level stated; no independent verification of patient data.
Limitations & review scope
- Author is Lyudmila Alekseevna Saikova; attribution to Pustozerov as dissertation author is incorrect.
- OCR reproduction; original scan and cohort overlap with the earlier papers require reconciliation.
- Neuromuscular disorders are not MS; heterogeneous treatments and uncontrolled observations limit inference.
Source checked 2026-10-03. This is a source-linked record, not a completed evidence review.
Inhibitory effect of 2-substituted benzimidazoles on lymphocyte mitogenesis is associated with AhR-dependent mechanisms
Format: Russian conference abstract; indexed PDF excerpt · Reviewed: Indexed abstract and table text reviewed
E. S. Sibiryak, S. V. Sadovnikov, S. V. Sibiryak · Medical Immunology. 2009;11(4–5):335. Conference abstract
At the reported Bemitil concentration, the table gives only 3±3% inhibition of mitogenesis. The combination with TCDD differed from the Bliss-model expectation. This supports an experimental interaction question, not a claim that Bemitil strongly suppresses human immunity.
- Population / setting
- Healthy-donor T cells stimulated with anti-CD3; benzimidazoles and TCDD interaction experiment
- What was checked
- Source text reviewed at the access level stated; no independent verification of patient data.
Limitations & review scope
- Conference abstract and indexed table excerpt, not a full clinical study.
- AhR involvement is a proposed mechanism; direct receptor binding and clinical immunosuppression were not demonstrated.
- No MS patients, demyelination outcome or clinical benefit assessment.
Source checked 2026-10-03. This is a source-linked record, not a completed evidence review.
Earlier neuromuscular records: 1991 report ↗ · 1992 report ↗. Shared investigators and potentially overlapping participants limit independent-replication claims.
Fatigue and metabolic-treatment context
Symptom outcomes, biochemical mechanisms and prescribing history should be read separately from relapse and disability-progression outcomes. The 2015 comparison studied Cytoflavin against a multi-drug regimen; it cannot establish benefit from an individual comparator drug.
Efficacy of Cytoflavin in patients with multiple sclerosis and fatigue
Format: Publisher full text · Reviewed: Methods and results reviewed
O. A. Mialovitska · Ukrainian Medical Journal. Published 18 March 2015
The Cytoflavin group’s MFIS score fell from 45.1±4.5 to 29±4.2 (reported within-group p<0.05). The comparator regimen included pentoxifylline, piracetam, meldonium and B vitamins. The result cannot be attributed to either piracetam or meldonium.
- Population / setting
- 62 screened; 53 with fatigue allocated to Cytoflavin (20) or conventional therapy (33)
- What was checked
- Source text reviewed at the access level stated; no independent verification of patient data.
Limitations & review scope
- Unequal groups; randomization and blinding are not established.
- 62 is the screened population, not the number allocated to treatment groups.
- A within-group change is not a demonstrated between-group effect; fatigue improvement is not disease modification.
Source checked 2026-10-03. This is a source-linked record, not a completed evidence review.
Bibliography, PDFs and recovery priorities
Access and review status are stated for each item. A located catalogue record or secondary citation is not a reviewed original study.
Cortexin neuroplasticity in MS — original PDF
S. V. Kotov; T. I. Yakushina; V. Yu. Lizhdvoy · Effective Pharmacotherapy. Neurology and Psychiatry. (3):14–16
Full article reviewed. Source version of cortexin-ms-2009, not an additional study.
Source record ↗Cyclophosphamide and Bemitil: antioxidant status and DNA integrity in SLE and rheumatoid arthritis
T. A. Lisitsyna · Dissertation author abstract; reported 23 pages
Original full text not recovered in this review. Potential cohort overlap with the 1999 SLE paper and 2000 patent.
Source record ↗Neuromuscular rehabilitation — publisher title/abstract mismatch
V. S. Lobzin; L. A. Saikova; V. D. Kosachev; V. G. Pustozerov; T. N. Vasilyeva · Neurology Bulletin. XXVI(1–2):51–54. DOI 10.17816/nb107044
English title describes traumatic/compressive neuropathies, but abstract concerns hereditary neuromuscular disorders. The program’s 1,000+ observations must not be represented as a Bemitil trial. Original metadata reconciliation pending.
Source record ↗Multiple sclerosis: metabolic disturbances and pathogenetic treatment — dissertation citation trail
Yu. N. Savchenko · Doctoral author abstract, Moscow, 36 pages; cited in later patent
Bibliographic citation in a later patent, not the original dissertation. Conflicting 1994/369-page references remain unresolved. Glycine-related claims require the original methods and results.
Source record ↗Myelinopathies and demyelinating diseases
A. P. Khokhlov; Yu. N. Savchenko · Moscow: Meditsina. 207,[1] pages. ISBN 5-225-00726-0
University catalogue confirms the book; full text not reviewed. Historical mechanisms are not clinical efficacy evidence.
Source record ↗Myelin metabolism paper — original article acquisition target
Khokhlov / Savchenko research trail; full author list pending · Zhurnal Nevropatologii i Psikhiatrii. 90(8); pages reported as 104–109, conflicting citation 104–113
Secondary bibliography trail only. Original title, page range, methods and results need reconciliation before a study record is created.
Source record ↗Membrane-destabilizing processes in erythrocytes of patients with multiple sclerosis
A. A. Sokolova · Candidate medical dissertation, Kazan
Dissertation reproduction describes membrane and oxidative-stress research. Biomarker associations do not establish efficacy of Bemitil or another treatment.
Source record ↗Historical Russian methodological recommendations No. 2000/166
Russian Ministry of Health · 17 November 2000; reproduced document
Historical adjunct-treatment context includes piracetam and Cerebrolysin. Not a trial, current guideline or endorsement of current MS care.
Source record ↗Historical multiple-sclerosis management protocol
Russian clinical protocol · 18 April 2005
Nootropic adjuncts, including piracetam and Cerebrolysin, appear with grade-C evidence. This historical recommendation does not establish modern clinical efficacy.
Source record ↗Marketing research on medicine provision for people with MS in Tyumen
O. V. Kolenchik · Dissertation, 114 pages
Catalogue/excerpt reviewed. Prescribing patterns are not efficacy outcomes; numerical utilization claims await original-document review.
Source record ↗Prospects of metabolic therapy in multiple sclerosis
G. N. Bisaga · Third RUCTRIMS congress abstract
Historical perspective acknowledges insufficient evidence for metabolic approaches. It is not a clinical trial; optimistic statements about individual treatments are not carried forward as current guidance.
Source record ↗Study of DNA damage of blood mononuclear cells in SLE by DNA-comets
See indexed author list · PMID 9532374
Related DNA-damage research lead. Do not assume a Bemitil intervention or MS population without reviewing the original report.
Source record ↗Still unresolved
- Whether the 2021 and 2025 Cortexin reports share participants.
- Complete results for all ten MS cases in the Bemitil patent.
- Original Lisitsyna dissertation, the 1993 Lobzin–Pustozerov article, and reconciliation of the 1994 publisher metadata.
- Savchenko’s original dissertation and myelin-metabolism paper; conflicting dates and page ranges remain flagged.
- Independent, adequately controlled MS trials with meaningful disability, relapse and safety outcomes.
Older encephalomyelopolyradiculoneuritis terminology does not automatically identify modern MS cohorts. Investigator biographies and unrelated alcohol-motivation research do not establish an MS treatment program.